Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.

Saved in:
Bibliographic Details
Title: Donor-derived regulatory dendritic cell infusion and early immunosuppressive drug withdrawal in living-donor liver transplantation: a phase I/IIa trial.
Authors: Humar A; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Hadjiyannis Y; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Macedo C; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Tran LM; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Elinoff BD; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Hughes CB; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Ganesh SR; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Zahorchak AF; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Ables EM; Department of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, Bloomington, IN, USA., Styn MA; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Landsittel D; Department of Biostatistics, School of Public Health and Health Professions, University at Buffalo, The State University of New York, New York, NY, USA., Zeevi A; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Lakkis FG; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Metes DM; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Thomson AW; Thomas E. Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. thomsonaw@upmc.edu.; Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. thomsonaw@upmc.edu.; Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, USA. thomsonaw@upmc.edu.
Source: Nature communications [Nat Commun] 2026 Apr 17; Vol. 17 (1). Date of Electronic Publication: 2026 Apr 17.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-71280-8